Behind The Deal: Nueterra Capital Invests in Infusion ExpressOctober 25, 2017 / Nueterra Capital Marketing
In this Kansas City Business Journal article Nueterra Capital CEO Jeremy Tasset outlines the decision to invest in Infusion Express which includes investing in health care companies that provide services that reduce costs for patients while providing better outcomes. For more details visit the link below.
Behind the deal: Why Nueterra invested in Infusion Express – Kansas City Business Journal
Jeremy Tasset, CEO of Nueterra Capital Management, said he had been following Infusion Express for several years before he decided to invest. The Leawood-based private equity investment company participated in Infusion Express’ first major funding round, led by San Francisco-based McKesson Ventures and Health Velocity Capital.
Subscribe To Our Newsletter
Join our mailing list to receive the latest news and updates from Nueterra Capital.